BioCorRx Inc. (BICX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 250K 500K 750K Q2 '21: 15.7K Q3 '21: 8.8K Q4 '21: 13.6K Q1 '22: 20.5K Q2 '22: 16K Q3 '22: 94.4K Q4 '22: 82.9K Q1 '23: 40.4K Q2 '23: 19.6K Q3 '23: 10.1K Q4 '23: 18.9K Q1 '24: 3.6K Q2 '24: 4K Q3 '24: 0 Q4 '24: 0 Q1 '25: 134.9K Q2 '25: 178.2K Q3 '25: 635.2K Q1 '26: 214.5K Q2 '26: 88K Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q2 '26

Gross Profit Quarterly

-150K 0 150K 300K 450K Q1 '11: -9.3K Q2 '11: 176.5K Q3 '11: 197.5K Q4 '11: 6.5K Q1 '12: 101.5K Q2 '12: 55K Q3 '12: -19.9K Q4 '12: 329K Q1 '13: 308.1K Q2 '13: 429.7K Q3 '13: 277.4K Q1 '14: 103.1K Q2 '14: 190.7K Q3 '14: 349.7K Q2 '11 Q4 '11 Q2 '12 Q4 '12 Q2 '13 Q1 '14 Q3 '14

Operating Income Quarterly

-2.1M -1.4M -700K 0 700K 1.4M 2.1M Q3 '21: -1.6M Q4 '21: -1.3M Q1 '22: -1.1M Q2 '22: -1.4M Q3 '22: -1M Q4 '22: -1.2M Q1 '23: -1.1M Q2 '23: -946.9K Q3 '23: -961.9K Q4 '23: -822.7K Q1 '24: -968.7K Q2 '24: -1.4M Q3 '24: -1.7M Q4 '24: -1.1M Q1 '25: -937.9K Q2 '25: -1.4M Q3 '25: -1.9M Q4 '25: -534.2K Q1 '26: -956K Q2 '26: -1.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-2.1M -1.4M -700K 0 700K 1.4M 2.1M Q3 '21: -1.4M Q4 '21: -1.2M Q1 '22: -945K Q2 '22: -1.3M Q3 '22: -951K Q4 '22: -1.2M Q1 '23: -1M Q2 '23: -923.5K Q3 '23: -867.3K Q4 '23: -969K Q1 '24: -1.2M Q2 '24: -1.2M Q3 '24: -1.5M Q4 '24: -1.2M Q1 '25: -841.4K Q2 '25: -1.2M Q3 '25: -1.9M Q4 '25: -471.2K Q1 '26: -831.2K Q2 '26: -964.8K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 50K 100K 150K Q1 '21: 632 Q2 '21: 1.8K Q3 '21: 1K Q4 '21: 2.4K Q1 '22: 1.5K Q2 '22: 2.7K Q3 '22: 2.3K Q4 '22: 8.7K Q1 '23: 8.7K Q2 '23: 10.4K Q3 '23: 3.9K Q4 '23: 13.1K Q1 '24: 1.7K Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 0 Q2 '25: 0 Q1 '26: 25.2K Q2 '26: 145K Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q2 '26

Operating Cash Flow Quarterly

-900K -600K -300K 0 300K 600K 900K Q3 '21: -621.7K Q4 '21: -647.6K Q1 '22: -872.7K Q2 '22: -351.7K Q3 '22: -367.8K Q4 '22: -449.6K Q1 '23: -397.4K Q2 '23: -571.5K Q3 '23: -350.5K Q4 '23: -533.8K Q1 '24: -339.7K Q2 '24: -151.9K Q3 '24: -357.5K Q4 '24: -247.2K Q1 '25: -689.6K Q2 '25: -126.5K Q3 '25: -634.4K Q4 '25: -847.7K Q1 '26: -433K Q2 '26: -440.3K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-1.1M -700K -350K 0 350K 700K 1.1M Q1 '13: -57.4K Q2 '13: -61K Q3 '13: -39.8K Q1 '14: -342 Q2 '14: 387.2K Q3 '14: -285.5K Q4 '14: 65.8K Q1 '16: -331.7K Q2 '16: -734.7K Q3 '16: -732.8K Q4 '16: -505.8K Q3 '18: -490.8K Q4 '18: -440.4K Q1 '19: -361K Q2 '19: -1M Q3 '19: -958.8K Q4 '19: -944.1K Q2 '13 Q2 '14 Q1 '16 Q4 '16 Q1 '19 Q4 '19

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 200M 400M 600M Q1 '15: 19.8M Q2 '15: 151.8M Q1 '16: 25.5M Q1 '17: 355.9M Q2 '17: 579.7M Q1 '18: 1.8M Q2 '18: 250.5M Q1 '19: 2.4M Q1 '20: 1.1M Q1 '21: 1.1M Q1 '22: 1.1M Q1 '23: 1.8M Q1 '24: 2.9M Q2 '24: 9.5M Q3 '24: 10.9M Q1 '25: 15.1M Q2 '25: 17M Q3 '25: 18.2M Q1 '26: 25.6M Q2 '26: 29.2M Q2 '15 Q2 '17 Q1 '19 Q1 '22 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q3 '16: -0.03 Q4 '16: -0.03 Q1 '17: -0.22 Q2 '17: -0.19 Q3 '17: -0.17 Q4 '17: -12.82 Q1 '18: -13.04 Q2 '18: -13.06 Q3 '18: -13.81 Q4 '18: -2.10 Q1 '19: -2.36 Q2 '19: -3.03 Q3 '19: -2.61 Q4 '19: -1.72 Q1 '25: -0.41 Q2 '25: -0.35 Q3 '25: -0.32 Q4 '25: -0.19 Q1 '26: -0.16 Q2 '26: -0.12 Q4 '16 Q3 '17 Q2 '18 Q1 '19 Q4 '19 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.